Can TikTok teach you how to 'get' an Ozempic prescription?

What did @realdrbae actually say?

A board-certified plastic surgeon posted a five-step guide to getting an Ozempic prescription, targeting the 6.6 million people who watched. The core advice: meet the clinical BMI thresholds, tell your doctor diet and exercise haven't worked, find a new doctor if yours won't listen, and ask for compounded semaglutide or tirzepatide if insurance denies coverage. The framing is practical, even blunt. "Obesity is a chronic disease" is the philosophical anchor of the whole thing.

That framing matters. A plastic surgeon giving GLP-1 prescribing advice is a little unusual, but nothing in the video is outside the scope of patient advocacy. The steps are structured around real clinical criteria, which is more than most viral Ozempic content can say. Still, one piece of advice deserves more scrutiny than the video gives it.

Does the science back this up?

The BMI thresholds cited are accurate and match current FDA labeling. Wegovy (semaglutide 2.4mg) is approved for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. That is not an opinion. It is the approved indication from the 2021 FDA approval, supported by the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), which showed 14.9% mean weight loss versus 2.4% for placebo over 68 weeks.

The claim that "obesity is a chronic disease" reflects the official position of the American Medical Association since 2013 and is supported by mechanistic research showing hormonal and neurological dysregulation in people with obesity (Schwartz et al., 2017, Cell Metabolism). The advice to seek a second opinion if your doctor is dismissive is consistent with patient rights and not medically problematic. The compounded semaglutide recommendation, though, is where things get complicated.

What did they get wrong (or right)?

Let's give credit first. The BMI thresholds are correct. The framing of obesity as a chronic condition rather than a willpower failure is supported by evidence. The suggestion to document failed diet and exercise attempts before your appointment is genuinely useful, practical advice that aligns with how prior authorization processes work in practice.

Here is the problem: the video treats compounded semaglutide and tirzepatide as straightforward substitutes for Wegovy and Zepbound. They are not. Compounded versions are not FDA-approved, are not required to meet the same purity and potency standards as brand-name drugs, and the FDA has issued multiple warnings about dosing errors and contamination risks from compounded GLP-1 products (FDA Drug Safety Communication, 2023). The video says compounded versions are "significantly less expensive," which is true, but skips entirely over the fact that quality varies dramatically by compounding pharmacy. Presenting them as a clean fallback option without that caveat is incomplete at best.

What should you actually know?

If you are considering a GLP-1 medication, the clinical eligibility criteria the video describes are real and worth knowing. A BMI over 30, or over 27 with a qualifying condition, is the documented threshold. Documenting your history with diet and lifestyle changes before your appointment is a legitimate strategy because prior authorization often requires it.

On compounded semaglutide: the FDA placed both semaglutide and tirzepatide on its drug shortage list, which temporarily allowed compounding. As of 2025, the FDA has determined the shortage is resolved, which has significant legal and regulatory implications for compounding pharmacies. If you are currently using or considering compounded GLP-1 therapy, the regulatory ground is shifting. Ask specific questions about the pharmacy's accreditation, third-party testing, and whether the product contains semaglutide base or a salt form, since some compounders use acetate or sodium salt versions whose pharmacokinetics differ from the studied drug.

• FDA-approved semaglutide doses for weight management start at 0.25mg weekly and titrate over months. Compounded versions have shown dosing inconsistencies in independent testing.
• Prior authorization denial rates for GLP-1s exceed 50% at many commercial insurers, so the advice to ask about compounding after denial reflects a real-world pattern.
• A plastic surgeon is not a prescriber of GLP-1 medications in most clinical contexts, so treat this as patient education, not a clinical consultation.